<DOC>
	<DOCNO>NCT01994889</DOCNO>
	<brief_summary>This Phase 3 study investigate efficacy , safety tolerability oral daily dose 20 mg 80 mg tafamidis meglumine capsule compare placebo subject either transthyretin genetic variant wild-type transthyretin result amyloid cardiomyopathy .</brief_summary>
	<brief_title>Safety Efficacy Tafamidis Patients With Transthyretin Cardiomyopathy</brief_title>
	<detailed_description>Phase 3 , multicenter , global , three-arm , parallel design , placebo-controlled , double-blind , randomize study determine efficacy , safety tolerability tafamidis clinical outcome ( all-cause mortality frequency cardiovascular-related hospitalization ) subject either transthyretin genetic variant wild-type transthyretin result amyloid cardiomyopathy .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Medical history Heart Failure ( HF ) least 1 prior hospitalization HF clinical evidence HF ( without hospitalization ) manifest sign symptom volume overload elevate intracardiac pressure ( e.g. , elevate jugular venous pressure , shortness breath sign pulmonary congestion xray auscultation , peripheral edema ) required/requires treatment diuretic improvement , Evidence cardiac involvement echocardiography enddiastolic interventricular septal wall thickness &gt; 12 mm , Presence amyloid deposit biopsy tissue presence variant TTR genotype and/or TTR precursor protein identification immunohistochemistry , scintigraphy mass spectrometry A New York Heart Association ( NYHA ) classification IV . Presence primary ( light chain ) amyloidosis . Prior liver heart transplantation implant cardiac mechanical assist device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>amyloidosis</keyword>
	<keyword>amyloid</keyword>
	<keyword>transthyretin</keyword>
	<keyword>TTR</keyword>
</DOC>